hVIVO to publish results on 25 April 2023

hVIVO supports UK Health Security Agency’s advice on hand hygiene to combat seasonal illnesses. Learn more about their vital role in public health here.

Discover how hVIVO Group’s innovative approach to human challenge trials and infectious disease expertise has shaped the future of pharmaceutical research in 2024.

hVIVO secures £11.5 million contract to test RSV drug candidate, highlighting the importance of human challenge models in addressing infectious diseases.

Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research on these biomarkers has largely focused

Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including

hVIVO plc (LON: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed an £11.5 million contract with

Multiplex PCR plays a crucial role in screening participants for human challenge studies and isolating new viruses, enhancing the integrity of research.

Discover the launch of hLab by hVIVO, a cutting-edge virology and immunology lab service revolutionizing vaccine development with advanced capabilities.

Clinical trials often offer compensation for participation, but payment structures vary. Learn about the factors that determine how much you can earn.

MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Yamin ‘Mo’ Khan, Chief Executive Officer, will be presenting